Medical Expulsive Therapy for Ureteral Stones: Stone Size Threshold
Medical expulsive therapy (MET) with alpha-blockers should be offered for ureteral stones <10 mm, with the greatest benefit demonstrated for distal ureteral stones >5 mm. 1
Stone Size Cutoffs by Guideline
The evidence shows some variation in recommended thresholds across major guidelines:
- AUA Guidelines (2007,2016): MET is an option for stones <10 mm, with specific recommendation for distal ureteral stones 1
- EAU Guidelines (2017,2025): MET with alpha-blockers is particularly recommended for distal ureteral stones >5 mm 2, 3
- Maximum observation period: 4-6 weeks from initial presentation 1, 2
Evidence-Based Rationale
The 10 mm threshold is supported by meta-analytic data showing:
- Alpha-blockers increase stone passage rates by 29% (CI: 20-37%) compared to controls 1
- Stone-free rates: 50% at 6 weeks and 86% at 12 weeks with MET versus 28% and 38% with placebo 4
- Optimal benefit zone: Stones 5-10 mm show significant benefit (RR 1.44,95% CI 1.22-1.68), while stones ≤5 mm show minimal additional benefit (RR 1.08) due to high spontaneous passage rates 5, 6
Clinical Algorithm for MET Candidacy
Eligible patients must have:
- Well-controlled pain
- No clinical evidence of sepsis
- Adequate renal functional reserve
- Stone size <10 mm on imaging 1
Strongest indication: Distal ureteral stones 5-10 mm 2, 3
Weaker indication: Stones <5 mm (high spontaneous passage rate makes benefit marginal) 5, 6
Medication Specifics
Alpha-blockers are the preferred agents (tamsulosin 0.4 mg daily is most studied) 1. Nifedipine shows marginal benefit with pooled-risk ratio 1.90 but is not statistically superior to alpha-blockers 1.
Critical Caveats
Patients must be counseled that:
- Alpha-blockers are used "off-label" for this indication 1
- Periodic imaging is mandatory to monitor stone position and hydronephrosis 1
- Treatment duration should not exceed 4-6 weeks to avoid irreversible kidney injury 1, 2
For stones >10 mm: While observation with MET is theoretically possible, most will require surgical intervention. No formal recommendation supports MET as primary therapy for this size category 1.
Additional Predictive Factors
Recent evidence identifies CT-based parameters that predict MET success beyond just stone size:
- Ureteral wall thickness >2.1-2.3 mm predicts failure 7, 8, 9
- Stone density >1078 HU reduces success 7
- Ureteral diameter >9.24 mm indicates lower success 7
These factors can refine patient selection but are not yet incorporated into formal guideline thresholds.